Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Early Life Child Micronutrient Status, Maternal Reasoning, and a Nurturing Household Environment have Persistent Influences on Child Cognitive Development at Age 5 years: Results from MAL-ED.

McCormick BJJ, Richard SA, Caulfield LE, Pendergast LL, Seidman JC, Koshy B, Roshan R, Shrestha R, Svensen E, Blacy L, Rasmussen Z, Maphula A, Scharf R, Nahar B, Haque S, Rasheed M, Oria R, Rogawski ET, Murray-Kolb LE, Acosta AM, de Burga RR, Chavez CB, Flores JT, Olotegui MP, Pinedo SR, Salas MS, Trigoso DR, Vasquez AO, Ahmed I, Alam D, Ali A, Bhutta ZA, Qureshi S, Rasheed M, Soofi S, Turab A, Zaidi AKM, Bodhidatta L, Mason CJ, Babji S, Bose A, George AT, Hariraju D, Jennifer MS, John S, Kaki S, Kang G, Karunakaran P, Koshy B, Lazarus RP, Muliyil J, Raghava MV, Raju S, Ramachandran A, Ramadas R, Ramanujam K, Bose A, Roshan R, Sharma SL, Sundaram E S, Thomas RJ, Pan WK, Ambikapathi R, Carreon JD, Charu V, Doan V, Graham J, Hoest C, Knobler S, Lang DR, McCormick BJJ, McGrath M, Miller MA, Mohale A, Nayyar G, Psaki S, Rasmussen Z, Richard SA, Seidman JC, Wang V, Blank R, Gottlieb M, Tountas KH, Amour C, Bayyo E, Mduma ER, Mvungi R, Nshama R, Pascal J, Swema BM, Yarrot L, Ahmed T, Ahmed AMS, Haque R, Hossain I, Islam M, Mahfuz M, Mondal D, Tofail F, Chandyo RK, Shrestha PS, Shrestha R, Ulak M, Bauck A, Black RE, Caulfield LE, Checkley W, Kosek MN, Lee G, Schulze K, Yori PP, Murray-Kolb LE, Ross AC, Schaefer B, Simons S, Scott SP, Pendergast L, Abreu CB, Costa H, Moura AD, Filho JQ, Havt A, Leite ÁM, Lima AAM, Lima NL, Lima IF, Maciel BLL, Medeiros PHQS, Moraes M, Mota FS, Oriá RB, Quetz J, Soares AM, Mota RMS, Patil CL, Bessong P, Mahopo C, Maphula A, Nyathi E, Samie A, Barrett L, Dillingham R, Gratz J, Guerrant RL, Houpt E, Petri WA, Platts-Mills J, Scharf R, Shrestha B, Shrestha SK, Strand T, Svensen E.

J Nutr. 2019 Aug 1;149(8):1460-1469. doi: 10.1093/jn/nxz055.

2.

Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.

Devereaux KA, Charu V, Zhao S, Charville GW, Bangs CD, van de Rijn M, Cherry AM, Natkunam Y.

Hum Pathol. 2018 Dec;82:39-45. doi: 10.1016/j.humpath.2018.06.034. Epub 2018 Jul 7.

PMID:
30539796
3.

Geographic transmission hubs of the 2009 influenza pandemic in the United States.

Kissler SM, Gog JR, Viboud C, Charu V, Bjørnstad ON, Simonsen L, Grenfell BT.

Epidemics. 2019 Mar;26:86-94. doi: 10.1016/j.epidem.2018.10.002. Epub 2018 Oct 10.

4.

Multinational patterns of seasonal asymmetry in human movement influence infectious disease dynamics.

Wesolowski A, Zu Erbach-Schoenberg E, Tatem AJ, Lourenço C, Viboud C, Charu V, Eagle N, Engø-Monsen K, Qureshi T, Buckee CO, Metcalf CJE.

Nat Commun. 2017 Dec 12;8(1):2069. doi: 10.1038/s41467-017-02064-4.

5.

Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.

Panjwani PK, Charu V, DeLisser M, Molina-Kirsch H, Natkunam Y, Zhao S.

Hum Pathol. 2018 Jan;71:91-99. doi: 10.1016/j.humpath.2017.10.029. Epub 2017 Nov 6.

PMID:
29122656
6.

Evaluating Post-Radiotherapy Laryngeal Function with Laryngeal Videostroboscopy in Early Stage Glottic Cancer.

Marciscano AE, Charu V, Starmer HM, Best SR, Quon H, Hillel AT, Akst LM, Kiess AP.

Front Oncol. 2017 Jun 12;7:124. doi: 10.3389/fonc.2017.00124. eCollection 2017.

7.

Peripheral nerve sheath tumors of the breast.

Charu V, Cimino-Mathews A.

Semin Diagn Pathol. 2017 Sep;34(5):420-426. doi: 10.1053/j.semdp.2017.05.011. Epub 2017 May 27. Review.

PMID:
28647116
8.

Digital image analysis supports a nuclear-to-cytoplasmic ratio cutoff value of 0.5 for atypical urothelial cells.

Hang JF, Charu V, Zhang ML, VandenBussche CJ.

Cancer Cytopathol. 2017 Sep;125(9):710-716. doi: 10.1002/cncy.21883. Epub 2017 Jun 5.

9.

Characterizing Highly Benefited Patients in Randomized Clinical Trials.

Charu V, Rosenberg PB, Schneider LS, Drye LT, Rein L, Shade D, Lyketsos CG, Frangakis CE.

Int J Biostat. 2017 May 20;13(1). pii: /j/ijb.2017.13.issue-1/ijb-2016-0045/ijb-2016-0045.xml. doi: 10.1515/ijb-2016-0045.

10.

Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.

VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH, Heaphy CM.

Cancer Cytopathol. 2017 Jul;125(7):544-551. doi: 10.1002/cncy.21857. Epub 2017 Apr 3.

11.

Human mobility and the spatial transmission of influenza in the United States.

Charu V, Zeger S, Gog J, Bjørnstad ON, Kissler S, Simonsen L, Grenfell BT, Viboud C.

PLoS Comput Biol. 2017 Feb 10;13(2):e1005382. doi: 10.1371/journal.pcbi.1005382. eCollection 2017 Feb.

12.

University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion).

Daniels M, Frangakis C, Charu V, Ghosh D.

Clin Trials. 2015 Aug;12(4):323-32. doi: 10.1177/1740774515590090. Epub 2015 Jun 10. No abstract available.

13.

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J.

J Clin Oncol. 2015 Nov 20;33(33):3921-9. doi: 10.1200/JCO.2014.58.7618. Epub 2015 Jun 8.

PMID:
26056177
14.

Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE.

Clin Infect Dis. 2015 Aug 15;61(4):506-14. doi: 10.1093/cid/civ331. Epub 2015 Apr 22.

15.

A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.

Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Schlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, Vescio R.

Support Care Cancer. 2015 Jun;23(6):1503-12. doi: 10.1007/s00520-014-2486-7. Epub 2014 Nov 5.

PMID:
25370889
16.

Demonstrating the use of high-volume electronic medical claims data to monitor local and regional influenza activity in the US.

Viboud C, Charu V, Olson D, Ballesteros S, Gog J, Khan F, Grenfell B, Simonsen L.

PLoS One. 2014 Jul 29;9(7):e102429. doi: 10.1371/journal.pone.0102429. eCollection 2014.

17.

Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF.

Radiology. 2014 Dec;273(3):746-58. doi: 10.1148/radiol.14140033. Epub 2014 Jul 15.

18.

Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997-2007.

Quandelacy TM, Viboud C, Charu V, Lipsitch M, Goldstein E.

Am J Epidemiol. 2014 Jan 15;179(2):156-67. doi: 10.1093/aje/kwt235. Epub 2013 Nov 4.

19.

Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review.

Bloom-Feshbach K, Alonso WJ, Charu V, Tamerius J, Simonsen L, Miller MA, Viboud C.

PLoS One. 2013;8(2):e54445. doi: 10.1371/journal.pone.0054445. Epub 2013 Feb 14.

20.

Mortality burden of the 2009-10 influenza pandemic in the United States: improving the timeliness of influenza severity estimates using inpatient mortality records.

Charu V, Simonsen L, Lustig R, Steiner C, Viboud C.

Influenza Other Respir Viruses. 2013 Sep;7(5):863-71. doi: 10.1111/irv.12096. Epub 2013 Feb 19.

21.

Improving the estimation of influenza-related mortality over a seasonal baseline.

Goldstein E, Viboud C, Charu V, Lipsitch M.

Epidemiology. 2012 Nov;23(6):829-38. doi: 10.1097/EDE.0b013e31826c2dda.

22.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
23.

Influenza-related mortality trends in Japanese and American seniors: evidence for the indirect mortality benefits of vaccinating schoolchildren.

Charu V, Viboud C, Simonsen L, Sturm-Ramirez K, Shinjoh M, Chowell G, Miller M, Sugaya N.

PLoS One. 2011;6(11):e26282. doi: 10.1371/journal.pone.0026282. Epub 2011 Nov 7.

24.

Mortality burden of the A/H1N1 pandemic in Mexico: a comparison of deaths and years of life lost to seasonal influenza.

Charu V, Chowell G, Palacio Mejia LS, Echevarría-Zuno S, Borja-Aburto VH, Simonsen L, Miller MA, Viboud C.

Clin Infect Dis. 2011 Nov;53(10):985-93. doi: 10.1093/cid/cir644. Epub 2011 Oct 5.

25.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.

26.

TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters.

Gabrail N, Sandler E, Charu V, Anas N, Lim E, Blaney M, Ashby M, Gillespie BS, Begelman SM.

J Vasc Interv Radiol. 2010 Dec;21(12):1852-8. doi: 10.1016/j.jvir.2010.09.002.

PMID:
21111365
27.

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group.

Curr Med Res Opin. 2009 Sep;25(9):2109-20. doi: 10.1185/03007990903084164.

PMID:
19601709
29.

Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.

Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB.

Oncologist. 2007 Dec;12(12):1416-24. doi: 10.1634/theoncologist.12-12-1416.

30.

A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.

Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.

Oncologist. 2007 Oct;12(10):1253-63.

31.

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.

Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.

Oncologist. 2007 Jun;12(6):727-37.

32.
33.

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.

Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.

Curr Med Res Opin. 2006 Jul;22(7):1403-13.

PMID:
16834839
34.
35.
36.
37.

Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.

Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP.

J Support Oncol. 2003 Jul-Aug;1(2):131-8.

PMID:
15352656
38.

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group.

Cancer. 2003 Dec 1;98(11):2473-82.

39.

Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.

Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.

Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):31-6.

Supplemental Content

Support Center